Zacks Analyst Blog Highlights: Semtech, UBS AG and Neurocrine Biosciences.CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day, the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Semtech (Nasdaq: SMTC SMTC Southern Maine Technical College SMTC Science/Mathematics/Technology Center (Central Michigan University) SMTC Saluda Mountain Telephone Company (Knoxville, Tennessee) SMTC Short-To-Medium Term Control ), UBS AG UBS AG (NYSE: UBS; SWX: UBSN; TYO: 8657 ) is a diversified global financial services company, with its main headquarters in London and New York. It is the world's largest manager of private wealth assets,, "the world's biggest manager of other people's money"[1] (NYSE NYSE See: New York Stock Exchange : UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System ) and Neurocrine Biosciences  This article about a company does not make it clear whether the subject meets the Wikipedia criteria for . , Inc. (Nasdaq: NBIX). See the latest posts to the Analyst Blog by visiting: http://at.zacks.com/?id=2673 Here are highlights from Tuesday's Analyst Blog: Good SMTC Entry Point Semtech (Nasdaq: SMTC) is a fabless supplier of analog and mixed signal semiconductor devices. The company has been diversifying the product portfolio, introducing new high-margin products and broadening the customer base. March quarter revenue was in-line with the consensus, while the EPS (Encapsulated PostScript) A PostScript file format used to transfer a graphic image between applications and platforms. EPS files contain PostScript code as well as an optional preview image in TIFF, WMF, PICT or EPSI, the latter being an ASCII-only format. exceeded consensus estimates. Next quarter's guidance is for 0-2% sequential growth, with flattish bookings and backlog. Design win activity remains strong and the pipeline looks healthy. The company has received a de-listing notice for the delay in filing its first quarter results, causing the share price to plunge. We believe this represents a buying opportunity and urge investors to accumulate shares. Expecting Solid UBS Performance We are reiterating our Buy on UBS AG (NYSE: UBS), and maintaining our target price at $65. UBS, expected to report second quarter results on August 15, had a 2-for-1 stock split on July 10, 2006. We have also adjusted our estimates for recent US$ depreciation against the Swiss franc. Our EPADS EPADS Earnings Per Average Diluted Share estimates are now $4.22 for 2006 and $4.52 for 2007. We expect continued solid operating performance to offset some credit quality weakening. UBS posted a 29% year-over-year gain in first quarter earnings to a record CHF CHF In currencies, this is the abbreviation for the Swiss Franc. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 3.2 billion due to robust capital markets. We believe UBS's $1.30 annual dividend, which provides a 2.6% yield, is safe. NBIX Upgraded to Hold Neurocrine Biosciences, Inc. (Nasdaq: NBIX) is focused on the discovery and development of medication for neurological disorders using its expertise in neuroscience, endocrine, and immunology disciplines has allowed it to develop drugs for anxiety, depression, insomnia, irritable bowel syndrome irritable bowel syndrome (IBS), condition characterized by frequently alternating constipation and diarrhea in the absence of any disease process. It is usually accompanied by abdominal pain, especially in the lower left quadrant, bloating, and flatulence. , multiple sclerosis, obesity, and diabetes. The company's lead product candidate, Indiplon, received an FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. "approvable" letter for the Capsule formulation and a "not approvable" letter for the Tablet formulation in May 2006. We no longer predict positive EPS for Neurocrine in 2006. In fact, our model continues to show operating losses through the end of the decade. Without Indiplon, the rest of the company is probably worth around $400 million as a development-stage biotech (including the $235 million in cash on the books at the end of the second quarter). This would be a target price of around $10.00 per share. With the stock trading at $9.25, we believe the market has removed all Indiplon expectations. This is the reason for our upgrade to Hold. We do not believe that Neurocrine has much upside past $12 without Indiplon. However, the stock is attractive below $8 based on earlier-stage candidates. Our target is $10 and we expect the stock to languish around this level for quite some time. See the latest posts to the Analyst Blog by visiting http://at.zacks.com/?id=2645 About Zacks Equity Research Zacks Equity Research provides the best of quantitative and qualitative analysis Qualitative Analysis Securities analysis that uses subjective judgment based on nonquantifiable information, such as management expertise, industry cycles, strength of research and development, and labor relations. to help investors know what stocks to buy and which to sell for the long-term. Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons. Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2674. About Zacks Zacks.com is a property of Zacks Investment Research Zacks Investment Research A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms. , Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion